MedTrace Logo

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

NCT02615054 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2024-04-11

No results posted yet for this study

Summary

This is for participants with a history of HER2-positive breast cancer and were treated with chemotherapy that increases the risk of abnormal heart function. Strain (a marker of heart function) is a new method of monitoring heart function in cancer patients and is measured with an ultrasound. Exercise testing is another method that can be used to monitor for abnormal heart function in cancer patients. The purpose of this study is to see if strain and exercise testing can be used to detect for late signs of heart damage from chemotherapy.

Conditions

  • Trastuzumab Cardiotoxicity
  • HER2-Positive Breast Cancer Survivors

Interventions

DEVICE

2D Echocardiogram

All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.

DEVICE

Cardiopulmonary exercise testing and post-CPET cardiac function

To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.

Sponsors & Collaborators

Principal Investigators

  • Anthony Yu, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-18
Primary Completion
2024-03-05
Completion
2024-03-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02615054 on ClinicalTrials.gov